Despite a 550% year-over-year increase in Q2 net earnings, Natco Pharma's shares are down 2% today

 Despite a 550% year-over-year increase in Q2 net earnings, Natco Pharma's shares are down 2% today

The stock of Natco Pharma has returned 26.22 percent during the last six months. The benchmark Nifty 50 index has returned 5.68 percent during the same time frame.

earnings-booking caused Natco Pharma shares to drop 2% during trading on November 15, despite the pharmaceutical business reporting a 55% increase in its Q2 net earnings. Natco Pharma's shares were trading at Rs 765.27 on the NSE at 12:39 p.m.

On November 14, Natco Pharma Ltd. announced a 55% increase in its consolidated net profit for the September quarter, primarily as a result of rising formulation exports and rising domestic agrochemical sales.

A press statement said that the net profit for the quarter was Rs 369 crore, compared to Rs 56.8 crore in the previous year. Over the course of the quarter, total revenues more than doubled to Rs 1,061 crore, up 134.7% from Rs 452 crore the previous year. An interim dividend of Rs 1.25 per share was announced by the firm.

The largest income contribution came from formulation exports, which brought in Rs 792 crore as opposed to Rs 283 crore the previous year. In the quarter under review, the crop health sciences sector generated Rs 56 crore, while the domestic formulations business made Rs 102 crore.

Pattern of Stock Shareholding by Natco Pharma

49.71 percent of the pharmaceutical and pharmaceutical industry is owned by promoters. The remaining 14.01 percent of the company is owned by domestic institutional investors (DIIs) and foreign institutional investors (FIIs), respectively.

Stock Performance of Natco Pharma

The stock of Natco Pharma has returned 26.22 percent during the last six months. The benchmark Nifty 50 index has returned 5.68 percent during the same time frame.